Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency
Authors:
- 1 January 2000
- journal article
- case report
- Published by Wiley in Haemophilia
- Vol. 6 (1) , 50-54
Abstract
The use of replacement FVII is critical to the successful treatment of life‐threatening bleeds in newborns and infants with severe FVII deficiency (100% between 30 and 180 min after each infusion with mean trough levels above 25% for all three dose levels. There was no evidence of hyper‐coagulation as indicated by measurements of the platelet count, D‐dimer, plasma protamine paracoagulant and fibrinogen levels in spite of high FVII:C concentration.In this infant, rFVIIa was well‐tolerated, maintained effective haemostasis with good clinical outcome, and produced consistent therapeutic mean trough levels above 25% FVII:C even at 15 μg kg–1 every 4 h.Keywords
This publication has 4 references indexed in Scilit:
- Development of a subdural vein thrombosis following aggressive factor VII replacement for postnatal intracranial haemorrhage in a homozygous factor VII-deficient infantHaemophilia, 1998
- Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiencyHaemophilia, 1997
- Distribution of factor VIII mRNA and antigen in human liver and other tissuesNature, 1985
- Factor VII deficiencyAmerican Journal of Hematology, 1981